FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Tuesday

 

Swedish Biotech Faces Another Phase III Flop in MS

















Teva and Active Biotech have failed Phase III with their MS drug laquinimod to treat the relapsing-remitting form of this disease.

Teva and Active Biotech have faced another setback with their long-expected successor to Teva’s Copaxone, laquinimod, for the treatment of MS. The drug failed to meet the primary endpoint, trying to improve the time to disease progression compared to placebo after three months in patients with the relapsing-remitting form of the disease.

The news comes not too long after the companies had to suspend the use of the highest dose of laquinimod due to cardiovascular side effects in the beginning of 2016. Yet, Teva and Active Biotech are encouraged by some positive results for a number of secondary endpoints with the lower-dose regimen, which convinced the companies to keep pushing ahead with ongoing trials of laquinimod in primary progressive MS and Huntington’s disease.

“Although we are disappointed by not meeting the primary endpoint, we did see positive results on a number of secondary and exploratory endpoints which fuels our belief in the potential of laquinimod as a possible treatment for neurodegenerative diseases,”  Teva CSO Michael Hayden, said in a statement.

However, with mounting evidence of laquinimod’s lack of efficacy, Active Biotech’s investors seem to be losing faith in one of the company’s most promising programs. Consequently, the shares of the Swedish biotech went down 66% following the news of the failure.

Since 2011, the company has been dealt a number of blows. First, weak clinical data on laquinimod undermined high expectations and raised doubts about the new drug, which was followed by a late-stage failure of the company’s tumor-targeting superantigen Anyara in a Phase II/III trial for renal cell cancer in 2013.

Finally, in 2015, Active Biotech’s partner Ipsen discontinued the development of the immunotherapy tasquinimod, overall cutting the biotech’s stock price by 97% since 2011.

Story Source: The above story is based on materials provided by LABIOTECH
Note: Materials may be edited for content and length

Labels: , , ,



Go to Newer News Go to Older News